ETOP IBCSG Partners Foundation

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC

Phase 2

Recruiting

Conditions: Non-small Cell Lung Cancer
Stage IV
Oligometastasis

Interventions: Drug: Durvalumab
Drug: Carboplatin
Drug: Paclitaxel
Radiation: Stereotactic body radiation therapy (SBRT)
Procedure: Surgical resection - definitive local treatment.
Radiation: Radical radiotherapy - definitive local treatment.
Drug: Tremelimumab

First Posted Date: 2019-05-29

Last Posted Date: 2024-12-20

Lead Sponsor: ETOP IBCSG Partners Foundation

Target Recruit Count: 96

Registration Number: NCT03965468

Locations: 🇨🇭
Kantonsspital Winterthur, Winterthur, Switzerland
🇮🇹
European Institute of Oncology, Milano, Italy
🇮🇹
Istituto Oncologico Veneto - Irccs, Padova, Italy

and more 12 locations

Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

Phase 3

Recruiting

Conditions: Breast Cancer Recurrent

Interventions: Drug: Palbociclib 125mg
Drug: Standard endocrine therapy

First Posted Date: 2019-01-29

Last Posted Date: 2024-08-13

Lead Sponsor: ETOP IBCSG Partners Foundation

Target Recruit Count: 400

Registration Number: NCT03820830

Locations: 🇨🇭
Brustzentrum Basel Bethesda Spital, Basel, Switzerland
🇨🇭
Fondazione Oncologia Lago Maggiore, Locarno, Switzerland
🇨🇭
BZ Bethanien, Zürich, Switzerland

and more 50 locations

BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

Phase 3

Active, not recruiting

Conditions: Pleural Mesothelioma Malignant Advanced

Interventions: Drug: Carboplatin
Drug: Pemetrexed
Drug: Bevacizumab
Drug: Atezolizumab

First Posted Date: 2018-12-03

Last Posted Date: 2024-07-09

Lead Sponsor: ETOP IBCSG Partners Foundation

Target Recruit Count: 401

Registration Number: NCT03762018

Locations: 🇧🇪
CHU Liege, Liege, Belgium
🇫🇷
Le Mans - CHG, Le Mans, France
🇨🇭
Kantonsspital Aarau, Aarau, Switzerland

and more 39 locations

To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)

Phase 2

Completed

Conditions: Estrogen Receptor Positive Tumor
Breast Cancer
HER2-positive Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Palbociclib
Drug: Trastuzumab
Drug: Letrozole
Drug: Pertuzumab

First Posted Date: 2018-08-23

Last Posted Date: 2024-12-13

Lead Sponsor: ETOP IBCSG Partners Foundation

Target Recruit Count: 147

Registration Number: NCT03644186

Locations: 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷
Centre Léon Berard, Lyon, France
🇮🇹
Centro di Riferimento Oncologico (CRO), Via Franco Gallini 2, Aviano, Pordenone, Italy

and more 51 locations

ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer

Phase 2

Terminated

Conditions: Non-small Cell Lung Cancer
Non-small Cell Lung Cancer Metastatic
Non-small Cell Lung Cancer Recurrent

Interventions: Drug: Alectinib

First Posted Date: 2018-02-26

Last Posted Date: 2022-08-24

Lead Sponsor: ETOP IBCSG Partners Foundation

Target Recruit Count: 14

Registration Number: NCT03445000

Locations: 🇳🇱
University Medical Center Maastricht, Maastricht, Netherlands
🇳🇱
The Netherlands Cancer Institute Amsterdam, Amsterdam, Netherlands
🇨🇭
Hôpital Universitaire de Genève, Genève, Switzerland

and more 16 locations

Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER)

Phase 2

Conditions: Non Small Cell Lung Cancer Metastatic

Interventions: Drug: Osimertinib
Drug: Bevacizumab

First Posted Date: 2017-04-28

Last Posted Date: 2022-08-24

Lead Sponsor: ETOP IBCSG Partners Foundation

Target Recruit Count: 155

Registration Number: NCT03133546

Locations: 🇮🇪
St. James Hospital, Dublin, Ireland
🇮🇪
Mid Western Cancer Centre, Limerick, Ireland
🇳🇱
VU University Medical Centre, Amsterdam, Netherlands

and more 22 locations

PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma

Phase 3

Completed

Conditions: Pleural Mesothelioma Malignant Advanced

Interventions: Drug: Pembrolizumab
Drug: Gemcitabine
Drug: Vinorelbine

First Posted Date: 2016-12-13

Last Posted Date: 2022-08-24

Lead Sponsor: ETOP IBCSG Partners Foundation

Target Recruit Count: 144

Registration Number: NCT02991482

Locations: 🇨🇭
Kantonsspital Aarau, Aarau, Switzerland
🇨🇭
Kantonsspital Winterthur, Winterthur, Switzerland
🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

and more 12 locations

MEtronomic TrEatment Option in Advanced bReast cAncer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Cyclophosphamide
Drug: Capecitabine
Drug: Vinorelbine

First Posted Date: 2016-11-03

Last Posted Date: 2024-02-26

Lead Sponsor: ETOP IBCSG Partners Foundation

Target Recruit Count: 140

Registration Number: NCT02954055

Locations: 🇮🇹
Ospedale di Bolzano Oncologia Medica Via lorenz Bohler 5, Bolzano, Italy
🇮🇹
"Antonio Perrino" Division of Medical Oncology Strada Statale 7 APPIA, Brindisi, Italy
🇮🇹
IRST IRCCS Division of medical oncology Via Maroncelli 40, Meldola, Italy

and more 17 locations

Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Palbociclib
Drug: Fulvestrant

First Posted Date: 2015-09-01

Last Posted Date: 2024-02-26

Lead Sponsor: ETOP IBCSG Partners Foundation

Target Recruit Count: 124

Registration Number: NCT02536742

Locations: 🇧🇪
CHU Liege, Liège, Belgium
🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇮🇹
Azienda USL4 Prato, Prato, Italy

and more 16 locations

NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer Stage III

Interventions: Drug: Nivolumab

First Posted Date: 2015-05-05

Last Posted Date: 2022-08-24

Lead Sponsor: ETOP IBCSG Partners Foundation

Target Recruit Count: 94

Registration Number: NCT02434081

Locations: 🇨🇭
HFR Fribourg- Hôpital cantonal, Fribourg, Switzerland
🇳🇱
VUMC, Amsterdam, Netherlands
🇨🇭
Kantonsspital Winterthur, Winterthur, Switzerland

and more 8 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy